NAION Eye Injury Claims Now in Federal MDL

Nationwide Representation by Wright McCall

Millions of Americans turned to popular GLP-1 drugs like Ozempic and Wegovy for diabetes management and weight loss.

Now, a growing number of patients are facing something far more serious:

Sudden, permanent vision loss.

Wright McCall is actively investigating claims involving these medications and representing individuals who developed Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) after using GLP-1 drugs.

---

The Drugs at the Center of These Lawsuits

GLP-1 receptor agonists are widely prescribed and heavily marketed—but new evidence suggests serious risks may not have been fully disclosed.

Medications Named in the Litigation

Manufactured by Novo Nordisk:

• Ozempic (semaglutide – diabetes)
• Wegovy (semaglutide – weight loss)
• Rybelsus (semaglutide – oral diabetes medication)

Manufactured by Eli Lilly and Company:

• Mounjaro (tirzepatide – diabetes)
• Zepbound (tirzepatide – weight loss)
• Trulicity (dulaglutide – diabetes)

These drugs work by mimicking a natural hormone to regulate blood sugar and suppress appetite—but their impact on the optic nerve is now under serious legal scrutiny.

---

The Breakthrough Study That Sparked Lawsuits

In July 2024, researchers from Harvard Medical School published a landmark study in JAMA Ophthalmology.

Their findings were alarming:

• Patients taking semaglutide had a 4x increased risk of developing NAION
• NAION can cause sudden, irreversible blindness

Despite this peer-reviewed evidence, lawsuits allege manufacturers failed to update warning labels or properly inform doctors and patients of the risk.

---

What Is NAION?

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a serious condition caused by sudden loss of blood flow to the optic nerve.

It often strikes without warning—and the damage is typically permanent.

Common Symptoms Include:

• Sudden vision loss in one eye (often upon waking)
• Blurred or dim vision
• Loss of color perception or contrast
• Partial blindness (top or bottom half of vision missing)
• No pain (which makes it harder to detect early)

For many patients, this condition changes everything overnight.

---

The Long-Term Impact of NAION

There is currently no FDA-approved treatment that reliably restores vision lost from NAION.

Even more concerning:

• The second eye is affected in 15–25% of patients within 5 years
• Many victims lose the ability to drive, work, or live independently

This isn’t just a side effect—it’s a life-altering injury.

---

Federal MDL Established for Vision Loss Cases

In December 2025, the U.S. Judicial Panel on Multidistrict Litigation created a new federal multidistrict litigation (MDL) specifically for NAION-related vision loss claims.

This decision is critical:

• The court recognized NAION as a distinct and serious injury
• Vision loss cases were separated from existing GLP-1 lawsuits
• Cases are now being centralized to streamline litigation and strengthen claims

This signals that the legal system is taking these injuries seriously—and the cases are moving forward.

---

Why These Lawsuits Are Being Filed

Claims against drug manufacturers focus on:

Failure to Warn

Patients and doctors were not adequately warned about the risk of blindness.

Negligence

Companies allegedly knew—or should have known—about the connection between GLP-1 drugs and NAION.

Defective Drug Design

The medications may carry risks that outweigh their intended benefits when not properly disclosed.

Misrepresentation

Drugs were marketed as safe and effective without full transparency about potential vision complications.

---

Who May Qualify for a Lawsuit?

You may be eligible if:

• You used Ozempic, Wegovy, Mounjaro, Trulicity, Zepbound, or Rybelsus
• You experienced sudden vision loss or were diagnosed with NAION
• You developed significant visual impairment after starting the medication

Family members may also have claims if a loved one suffered severe vision loss.

---

Compensation May Be Available For:

• Medical treatment and specialist care
• Loss of income or earning ability
• Permanent vision impairment
• Emotional distress and reduced quality of life
• Long-term disability and lifestyle impact

---

Why Timing Matters Right Now

The MDL has just been established.

That means:

• Cases are still being actively accepted
• Early filings can position claims more strongly
• Evidence and documentation are critical

This is the window to act.

---

How Wright McCall Builds These Cases

Wright McCall approaches these claims as high-stakes pharmaceutical litigation.

Our team will:

• Investigate your medication history
• Work with leading ophthalmology experts
• Analyze clinical data and research
• Build a trial-ready case from day one
• Fight for maximum compensation

You pay nothing unless we win.

---

Take Action Today

If you or a loved one experienced sudden vision loss after taking a GLP-1 drug, don’t ignore it.

You may have a case—and time matters.

Get a Free Case Review with Wright McCall

Find out if you qualify to join the growing number of claims being filed nationwide.